Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
MD-76R is an injectable contrast medium containing diatrizoate meglumine and diatrizoate sodium, used for radiographic visualization of internal body structures. It is a high-osmolality ionic contrast agent administered intravenously for diagnostic imaging procedures. The drug enhances X-ray and fluoroscopic imaging to improve visualization of vascular and organ systems.
Product is in late-stage maturity with declining market relevance as newer, lower-osmolality contrast agents dominate; expect lean commercial teams focused on cost management and niche hospital accounts.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
This product offers limited career growth opportunity due to its mature, declining lifecycle and lack of clinical innovation pipeline. Roles available are primarily defensive—focused on maintaining hospital relationships, managing generic competition, and ensuring compliance—rather than driving market growth or therapeutic advancement.
Worked on MD-76R at Guerbet? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.